Get the Stockscreener App
4.2787
0.36%
0.0687
Molecular Partners Ag Adr stock is traded at $4.2787, with a volume of 1,534.
It is up +0.36% in the last 24 hours and up +8.33% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
See More
Previous Close:
$4.21
Open:
$4.25
24h Volume:
1,534
Relative Volume:
0.26
Market Cap:
$159.42M
Revenue:
$786.00K
Net Income/Loss:
$-72.06M
P/E Ratio:
-2.2222
EPS:
-1.9254
Net Cash Flow:
$-59.83M
1W Performance:
+2.30%
1M Performance:
+8.33%
6M Performance:
-11.05%
1Y Performance:
+21.76%
1-Day Range:
$4.25
$4.25
1-Week Range:
$4.11
$4.25
52-Week Range:
$3.47
$5.36
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
4.25 | 157.92M | 786.00K | -72.06M | -59.83M | -1.9254 |
VRTX
Vertex Pharmaceuticals Inc
|
515.31 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.34 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.54 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.30 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | H.C. Wainwright | Buy |
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners (NASDAQ:MOLN) Shares Up 6.4%Still a Buy? - MarketBeat
Molecular Partners reports progress in MP0317 clinical trial - grafa.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress By Investing.com - Investing.com Nigeria
Molecular Partners advances MP0712 cancer trial - grafa.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress - Investing.com
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
A3CSB5 Forecast — Price Target — Prediction for 2027 - TradingView
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - GlobeNewswire Inc.
MOLN - Finviz
Molecular Partners reports phase 1 data for cancer drug MP0317 By Investing.com - Investing.com Australia
Molecular Partners reports phase 1 data for cancer drug MP0317 - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April - MarketBeat
Head & ShouldersStock ScreenerCharts - Finviz
Molecular Partners (NASDAQ:MOLN) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Molecular Partners stock rating at buy - Investing.com
H.C. Wainwright reiterates Molecular Partners stock rating at buy By Investing.com - Investing.com South Africa
Molecular Partners (NASDAQ:MOLN) Stock Price Up 5%Still a Buy? - MarketBeat
Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9% - MarketBeat
HC Wainwright Brokers Increase Earnings Estimates for MOLN - Defense World
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential By Investing.com - Investing.com South Africa
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential - Investing.com
Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Molecular Partners (NASDAQ: MOLN) outlines DARPin pipeline and cash into 2028 - Stock Titan
Will Petrobras Pull Off Q4 Earnings Beat on Strong Production? - TradingView
Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday - Defense World
Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5%Should You Sell? - MarketBeat
Brokers Offer Predictions for MOLN FY2025 Earnings - MarketBeat
What is HC Wainwright's Estimate for MOLN Q1 Earnings? - MarketBeat
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners to cut workforce by a quarter - Reuters
Citius Oncology (CTOR) Short Interest & Short Float | Updated Apr 2026 $CTOR - MarketBeat
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com
Molecular Partners reports 2024 annual results - Investing.com
Molecular Partners (MOLN) Stock Forecast and Price Target 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (MIRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
MAIA Biotechnology (MAIA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Acrivon Therapeutics (ACRV) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
MOLN LOSS ALERT: GLOBALLY RECOGNIZED ROSEN LAW FIRM - GlobeNewswire
US stock market gainers for the last week of April 2022 - Nairametrics
Molecular Partners ADRs Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Molecular Partners AG - GlobeNewswire
Annovis Bio (ANVS) Short Interest & Short Float | Updated Apr 2026 $ANVS - MarketBeat
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners - Reuters
Werewolf Therapeutics (HOWL) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Sensei Biotherapeutics (SNSE) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Molecular Partners (MOLN) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):